Anti-PD-L1 antibody [MIH6] - Low endotoxin, Azide free (ab80276)
Key features and details
- Rat monoclonal [MIH6] to PD-L1 - Low endotoxin, Azide free
- Suitable for: Flow Cyt
- Reacts with: Mouse
- Isotype: IgG2a
Get better batch-to-batch reproducibility with a recombinant antibody
- Research with confidence – consistent and reproducible results with every batch
- Long-term and scalable supply – powered by recombinant technology for fast production
- Success from the first experiment – confirmed specificity through extensive validation
- Ethical standards compliant – production is animal-free
Overview
-
Product name
Anti-PD-L1 antibody [MIH6] - Low endotoxin, Azide free
See all PD-L1 primary antibodies -
Description
Rat monoclonal [MIH6] to PD-L1 - Low endotoxin, Azide free -
Host species
Rat -
Tested applications
Suitable for: Flow Cytmore details -
Species reactivity
Reacts with: Mouse -
Immunogen
Tissue, cells or virus. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- Flow Cyt: C57BL/6 mouse splenocytes.
-
General notes
Please note the manufacture has changed and this item is currently only recommended for Flow Cytometry.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.20
Constituent: PBS -
Carrier free
Yes -
Concentration information loading...
-
Purity
Affinity purified -
Purification notes
<0.01 EU/ug Endotoxin (LAL). -
Clonality
Monoclonal -
Clone number
MIH6 -
Isotype
IgG2a -
Light chain type
kappa -
Research areas
Associated products
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
-
Recombinant Protein
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab80276 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Flow Cyt |
Use at an assay dependent concentration.
Use = 0.5 µg per million cells in 100 µl volume or 100 µl of whole blood. |
Notes |
---|
Flow Cyt
Use at an assay dependent concentration. Use = 0.5 µg per million cells in 100 µl volume or 100 µl of whole blood. |
Target
-
Function
Involved in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation and cytokine production. -
Tissue specificity
Highly expressed in the heart, skeletal muscle, placenta and lung. Weakly expressed in the thymus, spleen, kidney and liver. Expressed on activated T- and B-cells, dendritic cells, keratinocytes and monocytes. -
Sequence similarities
Belongs to the immunoglobulin superfamily. BTN/MOG family.
Contains 1 Ig-like C2-type (immunoglobulin-like) domain.
Contains 1 Ig-like V-type (immunoglobulin-like) domain. -
Cellular localization
Cell membrane and Endomembrane system. - Information by UniProt
-
Database links
- Entrez Gene: 60533 Mouse
- SwissProt: Q9EP73 Mouse
- Unigene: 245363 Mouse
-
Alternative names
- B7 H antibody
- B7 H1 antibody
- B7 homolog 1 antibody
see all
Images
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (13)
ab80276 has been referenced in 13 publications.
- Murad JP et al. Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity. Mol Ther 29:2335-2349 (2021). PubMed: 33647456
- Chen FF et al. Small-molecule PD-L1 inhibitor BMS1166 abrogates the function of PD-L1 by blocking its ER export. Oncoimmunology 9:1831153 (2020). PubMed: 33110706
- Gao H et al. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy. J Immunother Cancer 8:N/A (2020). PubMed: 33203663
- Sharma NS et al. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. J Clin Invest 130:451-465 (2020). PubMed: 31613799
- Brenner E et al. Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours. Nat Commun 11:1335 (2020). PubMed: 32165639